Drugs / GSK256073
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01147861 | Jul → Sep 2010 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00808093 | May → Aug 2008 | hyperlipidemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01376323 | Jul 2011 → Sep 2012 | type 2 diabetes mellitus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00903617 | Jun 2009 → Feb 2010 | hyperlipidemia | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK256073 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01376323 ↗ |
| Action | Activate | “HM74A agonist” NCT01147861 ↗ |
| Route | Oral | “GSK256073 1mg capsule taken orally twice a day” NCT01376323 ↗ |